New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors

Name: New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors
Brand: Springer Nature
SKU: 9783642800351
Availability: InStock

Best Price:
Buy New Perspectives in Molecular and Clinical Management of Gastrointestinal Tumors for $84.99 at @ Link.springer.com
No coupon is required — this is the standard retail price.

Set a price drop alert to never miss an offer.

1 Offer Price Range: $84.99 - $84.99

BEST PRICE

Single Product Purchase

$84.99

@ Link.springer.com BUY Now

Price Comparison

Seller	Contact Seller	List Price	On Sale	Shipping	Best Promo	Final Price	Volume Discount	Financing	Availability	Seller's Page
BEST PRICE 1 Product Purchase @ Link.springer.com		$84.99	$84.99			$84.99		See Site	In stock	Visit Store

Product Details

Brand

Springer Nature

Manufacturer

N/A

Part Number

GTIN

9783642800351

Condition

New

Product Description

This volume focuses on new and exciting approaches in the molecular and clinical management of gastrointestinal tumors. The first part presents recent insights into carcinogenesis, including alterations in cyclins and adhesion receptors, molecular structures which might be new targets of gene therapy. The second part of the volume offers new diagnostic tools, such as receptors for gastrointestinal hormones, proliferation markers, tumor suppressor proteins, and the multiple drug resistance gene, predicting response to therapy and prognosis in gastrointestinal tumors. The third part gives an update of successful approaches in primary and secondary prevention of colorectal carcinoma. Nutritional factors and pharmacologic agents can clearly decrease the risk, and fecal occult blood tests and endoscopy can reduce the mortality in colorectal carcinoma. Laparoscopic staging with subsequent biopsy of suspicious lymph nodes provides essential information in esophageal and gastric cancer. In locally advanced gastric cancer, preoperative chemotherapy provides sufficient evidence to investigate this approach as compared to primary surgery. Standards have recently been established in the adjuvant treatment of patients with gastrointestinal carcinoma, and promising new drugs, including monoclonal antibodies, thymidylate synthase, and topoisomerase inhibitors, as well as taxoids, are currently being tested in phase I, II, and III trials of gastrointestinal tumors.

Available Colors

N/A

Available Sizes

N/A